CA2289094A1 - New cysteine derivatives, processes for their production, and pharmaceuticals containing them - Google Patents
New cysteine derivatives, processes for their production, and pharmaceuticals containing them Download PDFInfo
- Publication number
- CA2289094A1 CA2289094A1 CA002289094A CA2289094A CA2289094A1 CA 2289094 A1 CA2289094 A1 CA 2289094A1 CA 002289094 A CA002289094 A CA 002289094A CA 2289094 A CA2289094 A CA 2289094A CA 2289094 A1 CA2289094 A1 CA 2289094A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- aromatic
- alkyl group
- optionally substituted
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A compound represented by general formula (I), which binds and inhibits matrix metalloproteinases (MMPs), wherein the cysteine moiety contains an unprotected thiol group, the cysteine moiety is in the L- or D-configuration wherein A
denotes -CO-, SO2-, -NH-CO-, or -O-CO-, R1 denotes hydrogen, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by halogen, mercapto, hydroxy, alkoxy, amino or nitro, or by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof. R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof, processes for the preparation, pharmaceutical compositions and their use in medicine.
denotes -CO-, SO2-, -NH-CO-, or -O-CO-, R1 denotes hydrogen, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by halogen, mercapto, hydroxy, alkoxy, amino or nitro, or by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof. R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof, processes for the preparation, pharmaceutical compositions and their use in medicine.
Description
NEW CYSTEINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICALS CONTAIrIING THEM
The invention comprises new matrix metalloproteinase inhibitors that are based on the use of the amino acid L- or v-cysteine which is derivatized at the amino and carboxyl function with non-peptidic type groups (formula I). The invention comprises methods for the production of the inhibitors and their use in the field of therapeutics.
The family of matrix metalloproteases (MIvv>Ps) has become a major target for drug design, since these enzymes are involved in tissue remodeling and connective tissue turnover, and thus in several diseases where (i) rapid extracellular matrix degradation is taking place, e.g. during congestive heart failure and extravasion of highly metastatic tumor cells, or (ii) slow extracellular matrix degradation is occurring, e.g.
artherosclerotic lesion formation and rupture. cartilage matrix loss in osteoarthritis, bone ?0 matrix degradation in osteoporosis, gingival degradation in periodontal disease. matrix remodeling and deposition in Alzheimer plaque formation and rheumatoid arthritis.
The MIVVIP family currently includes fourteen members, ten of which are secreted from the cells in a soluble form and four members are membrane-bound enzymes. The MNiPs ?5 are zinc dependent and calcium requiring enzymes which are inhibited by one of the members of the tissue inhibitor of metalloproteinase (TINiP) family. Synthetic inhibitors of this class of enzymes have been developed as hydroxamates, N-carboxvalkyl derivatives, phosphonamidates and phosphinates as well as by using thiol groups as ligands for the active-site zinc atom.
The invention comprises new matrix metalloproteinase inhibitors that are based on the use of the amino acid L- or v-cysteine which is derivatized at the amino and carboxyl function with non-peptidic type groups (formula I). The invention comprises methods for the production of the inhibitors and their use in the field of therapeutics.
The family of matrix metalloproteases (MIvv>Ps) has become a major target for drug design, since these enzymes are involved in tissue remodeling and connective tissue turnover, and thus in several diseases where (i) rapid extracellular matrix degradation is taking place, e.g. during congestive heart failure and extravasion of highly metastatic tumor cells, or (ii) slow extracellular matrix degradation is occurring, e.g.
artherosclerotic lesion formation and rupture. cartilage matrix loss in osteoarthritis, bone ?0 matrix degradation in osteoporosis, gingival degradation in periodontal disease. matrix remodeling and deposition in Alzheimer plaque formation and rheumatoid arthritis.
The MIVVIP family currently includes fourteen members, ten of which are secreted from the cells in a soluble form and four members are membrane-bound enzymes. The MNiPs ?5 are zinc dependent and calcium requiring enzymes which are inhibited by one of the members of the tissue inhibitor of metalloproteinase (TINiP) family. Synthetic inhibitors of this class of enzymes have been developed as hydroxamates, N-carboxvalkyl derivatives, phosphonamidates and phosphinates as well as by using thiol groups as ligands for the active-site zinc atom.
an N-terminal propeptide of about 80 residues. The propeptide forms a separate smaller domain that contains three oc-helices and an extended peptide that occupies the active site. The catalytic domain in all these structures contains two Zn2+ ions, i.
e. a "structural"
zinc ion and a "catalytic" zinc ion. The "catalytic" zink ion is coordinated by the side chains of three histidyl residues of the consensus sequence HEX~GXXI~i. The fourth ligand of the "catalytic" zink in the inhibited enzymes is a coordinating group of the inhibitors like the hydroxamate or carboxylate; in the pro-N» propeptide it is the thiol group of the cysteine residue( 1 ).
Correspondingly, the thiol-based collagenase inhibitors, proposed so far, are generally of peptidic structure containing cysteine or cysteine-like amino acids and their design was based on the binding mode of the substrate and more recently, of the the cysteine-containing propeptide.
The present invention relates to a new class of M1VVIP inhibitors which were derived from cysteine in a non-peptidic manner as shown in the general formula I, processes for the preparations, and pharmaceutical compositions containing these compounds and their therapeutical use in medicine, H O
I
Ri,A~N NCR
I
H
SH tn wherein A denotes -CO-, -S02-, -NH-CO-, or -O-CO-R, denotes hydrogen, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C,-C~s alkyl group substituted by halogen, mercapto, hydroxy, alkoxy, amino or nitro, or by carbocyclic aromatic or non aromatic ring systems which WO 98/50351 PCT/EP98102b54 are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C,-C,3 alkyl group substituted by carbocycGc aromatic or non aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
With respect to formula I R or/and R, represent a branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms selected from methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, hexyl, heptyl, octyi, nonyl, decyl, undecyl, dodecyi, etc., vinyl, etc. as well as the corresponding alkinyl groups e. g. acetylene.
The carbocyclic aromatic or non aromatic substituents for said alkyl groups are selected from C3-Cs cycioalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or 1 S C6-C,4 carbocyclic aromatic substituents such as phenyl, naphtyl, or anthranyl, or heierocyclic non aromatic substituents such as pyrolidinyl, piperidinyl, piperazinyl, or morpholinyl, or heterocyclic aromatic substituents such as pyrrolyl, pyridinyl, furyl, thienyl, thiazolyl, imidazolyl, pyrimidinyi, purinyl, indolyl, quinolyl, carbazolyl.
The carbocyclic aromatic or non aromatic ring systems respectively heterocycles can optionally be substituted once or several times for example by halogen-, vitro-, hydroxy-, C,-C6 alkyl-, C,-C6 alkoxy-, amino-, mercapto-, carboxyl-, cyano-, or sulfonyl groups.
If A denotes -CO-, the residue R,CO- is preferably selected from the residues of the following carboxyclic acids:
Formic Acid, Acetic acid, Propionic acid, Hexanoic acid, Lauric acid, Myrisic acid, Paimitic acid, Stearic acid, Arachidonic acid, Behenic acid, Octadecenoic acid, Linoleic acid, Linolenic acid, 3-Mercaptopropionic acid, Glyoxylic acid, Malonic acid, Succinic acid, 4-Aminobutanoic acid, 6-Aminocaproic acid, 3-Nitropropionic acid, Naphthylacetic acid, 4-Aminophenylacetic acid, Acrylic acid, Cinnamic acid, 4-Amino-cinnamic acid, Aminocrotonic acid, Fumaric acid, Maleinic acid, Phthalic acid, Benzoic acid, Nitrobenzoic acid, 3-Aminobenzoic acid, 4-Aminobenzoic acid, Anthranilic acid, Salicilic acid, 3-Amino-salicilic acid, 4-Amino-salicilic acid, 5-Amino-salicilic acid, Naphthoic WO 98!50351 PCT/EP98/02654 acid, p-Phenylbenzoic acid, Phenanthroic acid, Nicotinic acid, 3-Aminopyrazin-carbonic acid, Pyridine carboxylic acid, Piperazine carboxylic acid, Piperidine carboxylic acid.
If A denotes -SOZ, the residue R,SOz- is preferably selected from the residues of the following sulforlic acids:
Methanesuifonic acid, Ethanesulfonic acid, Propane sulfonic acid, 3-Hydroxypropane sulfonic acid, Ortharulic acid (aniline- 2- sulfonic acid), Naphthalenesulfonic acid, Naphthylamine sulfonic acid, Aminomethane sulfonic acid, 2-Mercaptoethane sulfonic acid, 2-Chloroethane sulfonic acid, N,N'-Dimethylsulfamic acid, Piperidine sulfonic acid, 5- (2- Aminoethylamino)- 1- naphthalene- sulfonic acid , Iodoxyquinolinesulfonic acid, Pyridine- 3- sulfonic acid, p- Toluenesulfonic acid, 2- (p-Toluidino)naphthalene- 6-sulfonic acid, Decyl methanesulfonic acid, 2- [(2- Amino- 2-oxoethyl)amino]ethanesulfonic acid, 2- (N- Cyclohexylamino)ethanesulfonic acid, 2-[bis(2- Hydroxyethyl)amino]ethanesulfonic acid, N- 2- Hydroxyethylpiperazine-ethanesulfonic acid, N- tris(Hydroxymethyl)methyl- 2- amino- ethanesulfonic acid, 2- (N-Morpholino)ethanesulfonic acid, Piperazine- N,N- bis(2- ethanesulfonic acid), 3- (2-Pyridyl)- 5,6- bis(4- phenylsulfonic acid)- 1,2,4- triazine.
If A denotes -NHCO-, the residue R,-NH-CO- is preferably selected from the residues of the following urea derivatives:
n- Butyl-, R- (+)- alpha- Phenylethyl-, R-(-)-1-(1-Naphthyl)-ethyl-, Ethyl-, Propyl-, Hexyl-, Octyl-, Benzyl-, Chlorobenry!-, Methylbenzyl-, 3-Picolyl-, 2-(Aminomethyl)-pyridyl urea.
If A denotes -O-CO-, the residue R,-O-CO- is preferably selected from the residues of the following Carbamates:
Methyl carbamate, Ethyl carbamate, 9-Fluorenylmethyl carbamate, 9-(2-Sulfo)fluorenylmethyl carbamate, 9-(2,7-Dibromo)fluorenylmethyl carbamate, 4-Methoxyphenacyl carbamate, 2,2,2-Trichloroethyl carbamate, 2-Phenylethyl carbamate, 1-(1-Adamantyl)-1-methylethyl carbamate, I,1-Dimethyl-2-haloethyi carbamate, 1-Methyl-1-(4-biphenyl)-1-methylethyl carbamate, 2-(2'-Pyridyl)ethyl carbamate, Adamantyl carbamate, Vinyl carbamate, Allyi carbamate, 1-Isopropylallyl carbamate, 4-Nitrocinnamyl carbamate, 8-Quinolyl carbamate, Cyclohexyl carbamate, Benzyl carbamate, p-Methoxybenzyi carbamate, p-Nitrobenzyl carbamate, p-Bromobenzyl carbamate, 9-Anthrylmethyi carbamate, diphenylmethyl carbamate, 2-Methylsulfonylethyl 5 carbamate, 2-(p-Toluenesulfonyl)ethyl carbamate, 4-Methylthiophenyl carbamate.
R is preferably selected from the following residues:
Ethyl-, Propyl-, Hexyl-, Octyl-, Benzyi-, 4-Chlorobenzyl-, 4-Methylbenzyl-, 3-Picolyl-, 2-(methyl)-pyridyl-, 4-(methyl)pyridyl-, 3-Phenylpropyl-, 4-Phenylbutyl-, 2-(p-Tolyl)ethyl- , 3-Nitrobenzyl-, Benzylethyl-, 2-Phenylethyl-, Adamantyl-, Pyridyl-, Phenyl, Cholestenyi-, Naphthyl-, 4-Phenoxy-phenyl or indolylethyl.
Preferred compounds according to formula I are compounds of example 5-22, and of the following table:
R,-CO R
Form 1- Be 1-Phen 1- Na hth 1-Na hth facet 1- 3-Picol 1-4-Bi hen 1- Z-Phen leth 1-R,-SO= R
'dine-3-sulfon i- Phen i ro 1--Toluenesulfon 1- -Chlorobe 1-R~-NH-CO R
Be 1- P 'd 1-R,-O-CO R
2-Phen leth 1- 4-Phen o hen Be 1- 2-Phen leth l-2-(p-Toluenesulfonyi)ethyl--Benzyl-The compounds according to the formula I consist of three parts which have different structures and different properties. The chelating group SH for the active-site Zn2+ ion, the hydrophobic groups R, or R to interact with the hydrophobic S~, protein pocket as well as to contribute to additional hydrophobic interactions along the P' substrate binding cleft.
Inhibitors of the general formula I allow for developing selective inhibitors of the different MMPs as required for their differentiated pathological implications e.g.
osteoporosis rheumatoid arthritis, periodontal disease, artherosclerosis, congestive heart failure, tumor invasion and metastasis and angiogenesis.
It is known that there are similar compounds described in the literature.
However, these are peptidic compounds and they display a worse half life time in human plasma.
The chemical structure of the cysteine derivatives was choosen in view of increased metabolic stability. Correspondingly, the amino group was acylated with carboxylic acids to produce amides, but preferentially urethanyl derivatives known to be more stable to enzymatic metabolism. Similarly, the C-terminal carboxyl function was derivatized as amide instead of esterification to avoid fast clearance rates due to hydrolysis of the esters by lipases. Moreover, N-alkyl and N-aryl amides were selected which are known to be more stable towards peptidases.
For the synthesis of the inhibitors classical procedures of organic synthesis were applied (2). Related L- and D-cystine derivatives of formula II were prepared according to standard procedures of peptide chemistry and then amidated with EDCIlHOBt according to Scheme 1. Subsequent reduction of the cystine compounds of formula III to the cysteine derivatives of Formula I was performed with reducing agents like mercaptanes or preferentially with phosphines like tributylphosphine, as shown in scheme 1.
______ _. __.__ _. _ ~_.~_ _ ~_ ~_ _._. T
e. a "structural"
zinc ion and a "catalytic" zinc ion. The "catalytic" zink ion is coordinated by the side chains of three histidyl residues of the consensus sequence HEX~GXXI~i. The fourth ligand of the "catalytic" zink in the inhibited enzymes is a coordinating group of the inhibitors like the hydroxamate or carboxylate; in the pro-N» propeptide it is the thiol group of the cysteine residue( 1 ).
Correspondingly, the thiol-based collagenase inhibitors, proposed so far, are generally of peptidic structure containing cysteine or cysteine-like amino acids and their design was based on the binding mode of the substrate and more recently, of the the cysteine-containing propeptide.
The present invention relates to a new class of M1VVIP inhibitors which were derived from cysteine in a non-peptidic manner as shown in the general formula I, processes for the preparations, and pharmaceutical compositions containing these compounds and their therapeutical use in medicine, H O
I
Ri,A~N NCR
I
H
SH tn wherein A denotes -CO-, -S02-, -NH-CO-, or -O-CO-R, denotes hydrogen, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C,-C~s alkyl group substituted by halogen, mercapto, hydroxy, alkoxy, amino or nitro, or by carbocyclic aromatic or non aromatic ring systems which WO 98/50351 PCT/EP98102b54 are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C,-C,3 alkyl group substituted by carbocycGc aromatic or non aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
With respect to formula I R or/and R, represent a branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms selected from methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, hexyl, heptyl, octyi, nonyl, decyl, undecyl, dodecyi, etc., vinyl, etc. as well as the corresponding alkinyl groups e. g. acetylene.
The carbocyclic aromatic or non aromatic substituents for said alkyl groups are selected from C3-Cs cycioalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or 1 S C6-C,4 carbocyclic aromatic substituents such as phenyl, naphtyl, or anthranyl, or heierocyclic non aromatic substituents such as pyrolidinyl, piperidinyl, piperazinyl, or morpholinyl, or heterocyclic aromatic substituents such as pyrrolyl, pyridinyl, furyl, thienyl, thiazolyl, imidazolyl, pyrimidinyi, purinyl, indolyl, quinolyl, carbazolyl.
The carbocyclic aromatic or non aromatic ring systems respectively heterocycles can optionally be substituted once or several times for example by halogen-, vitro-, hydroxy-, C,-C6 alkyl-, C,-C6 alkoxy-, amino-, mercapto-, carboxyl-, cyano-, or sulfonyl groups.
If A denotes -CO-, the residue R,CO- is preferably selected from the residues of the following carboxyclic acids:
Formic Acid, Acetic acid, Propionic acid, Hexanoic acid, Lauric acid, Myrisic acid, Paimitic acid, Stearic acid, Arachidonic acid, Behenic acid, Octadecenoic acid, Linoleic acid, Linolenic acid, 3-Mercaptopropionic acid, Glyoxylic acid, Malonic acid, Succinic acid, 4-Aminobutanoic acid, 6-Aminocaproic acid, 3-Nitropropionic acid, Naphthylacetic acid, 4-Aminophenylacetic acid, Acrylic acid, Cinnamic acid, 4-Amino-cinnamic acid, Aminocrotonic acid, Fumaric acid, Maleinic acid, Phthalic acid, Benzoic acid, Nitrobenzoic acid, 3-Aminobenzoic acid, 4-Aminobenzoic acid, Anthranilic acid, Salicilic acid, 3-Amino-salicilic acid, 4-Amino-salicilic acid, 5-Amino-salicilic acid, Naphthoic WO 98!50351 PCT/EP98/02654 acid, p-Phenylbenzoic acid, Phenanthroic acid, Nicotinic acid, 3-Aminopyrazin-carbonic acid, Pyridine carboxylic acid, Piperazine carboxylic acid, Piperidine carboxylic acid.
If A denotes -SOZ, the residue R,SOz- is preferably selected from the residues of the following sulforlic acids:
Methanesuifonic acid, Ethanesulfonic acid, Propane sulfonic acid, 3-Hydroxypropane sulfonic acid, Ortharulic acid (aniline- 2- sulfonic acid), Naphthalenesulfonic acid, Naphthylamine sulfonic acid, Aminomethane sulfonic acid, 2-Mercaptoethane sulfonic acid, 2-Chloroethane sulfonic acid, N,N'-Dimethylsulfamic acid, Piperidine sulfonic acid, 5- (2- Aminoethylamino)- 1- naphthalene- sulfonic acid , Iodoxyquinolinesulfonic acid, Pyridine- 3- sulfonic acid, p- Toluenesulfonic acid, 2- (p-Toluidino)naphthalene- 6-sulfonic acid, Decyl methanesulfonic acid, 2- [(2- Amino- 2-oxoethyl)amino]ethanesulfonic acid, 2- (N- Cyclohexylamino)ethanesulfonic acid, 2-[bis(2- Hydroxyethyl)amino]ethanesulfonic acid, N- 2- Hydroxyethylpiperazine-ethanesulfonic acid, N- tris(Hydroxymethyl)methyl- 2- amino- ethanesulfonic acid, 2- (N-Morpholino)ethanesulfonic acid, Piperazine- N,N- bis(2- ethanesulfonic acid), 3- (2-Pyridyl)- 5,6- bis(4- phenylsulfonic acid)- 1,2,4- triazine.
If A denotes -NHCO-, the residue R,-NH-CO- is preferably selected from the residues of the following urea derivatives:
n- Butyl-, R- (+)- alpha- Phenylethyl-, R-(-)-1-(1-Naphthyl)-ethyl-, Ethyl-, Propyl-, Hexyl-, Octyl-, Benzyl-, Chlorobenry!-, Methylbenzyl-, 3-Picolyl-, 2-(Aminomethyl)-pyridyl urea.
If A denotes -O-CO-, the residue R,-O-CO- is preferably selected from the residues of the following Carbamates:
Methyl carbamate, Ethyl carbamate, 9-Fluorenylmethyl carbamate, 9-(2-Sulfo)fluorenylmethyl carbamate, 9-(2,7-Dibromo)fluorenylmethyl carbamate, 4-Methoxyphenacyl carbamate, 2,2,2-Trichloroethyl carbamate, 2-Phenylethyl carbamate, 1-(1-Adamantyl)-1-methylethyl carbamate, I,1-Dimethyl-2-haloethyi carbamate, 1-Methyl-1-(4-biphenyl)-1-methylethyl carbamate, 2-(2'-Pyridyl)ethyl carbamate, Adamantyl carbamate, Vinyl carbamate, Allyi carbamate, 1-Isopropylallyl carbamate, 4-Nitrocinnamyl carbamate, 8-Quinolyl carbamate, Cyclohexyl carbamate, Benzyl carbamate, p-Methoxybenzyi carbamate, p-Nitrobenzyl carbamate, p-Bromobenzyl carbamate, 9-Anthrylmethyi carbamate, diphenylmethyl carbamate, 2-Methylsulfonylethyl 5 carbamate, 2-(p-Toluenesulfonyl)ethyl carbamate, 4-Methylthiophenyl carbamate.
R is preferably selected from the following residues:
Ethyl-, Propyl-, Hexyl-, Octyl-, Benzyi-, 4-Chlorobenzyl-, 4-Methylbenzyl-, 3-Picolyl-, 2-(methyl)-pyridyl-, 4-(methyl)pyridyl-, 3-Phenylpropyl-, 4-Phenylbutyl-, 2-(p-Tolyl)ethyl- , 3-Nitrobenzyl-, Benzylethyl-, 2-Phenylethyl-, Adamantyl-, Pyridyl-, Phenyl, Cholestenyi-, Naphthyl-, 4-Phenoxy-phenyl or indolylethyl.
Preferred compounds according to formula I are compounds of example 5-22, and of the following table:
R,-CO R
Form 1- Be 1-Phen 1- Na hth 1-Na hth facet 1- 3-Picol 1-4-Bi hen 1- Z-Phen leth 1-R,-SO= R
'dine-3-sulfon i- Phen i ro 1--Toluenesulfon 1- -Chlorobe 1-R~-NH-CO R
Be 1- P 'd 1-R,-O-CO R
2-Phen leth 1- 4-Phen o hen Be 1- 2-Phen leth l-2-(p-Toluenesulfonyi)ethyl--Benzyl-The compounds according to the formula I consist of three parts which have different structures and different properties. The chelating group SH for the active-site Zn2+ ion, the hydrophobic groups R, or R to interact with the hydrophobic S~, protein pocket as well as to contribute to additional hydrophobic interactions along the P' substrate binding cleft.
Inhibitors of the general formula I allow for developing selective inhibitors of the different MMPs as required for their differentiated pathological implications e.g.
osteoporosis rheumatoid arthritis, periodontal disease, artherosclerosis, congestive heart failure, tumor invasion and metastasis and angiogenesis.
It is known that there are similar compounds described in the literature.
However, these are peptidic compounds and they display a worse half life time in human plasma.
The chemical structure of the cysteine derivatives was choosen in view of increased metabolic stability. Correspondingly, the amino group was acylated with carboxylic acids to produce amides, but preferentially urethanyl derivatives known to be more stable to enzymatic metabolism. Similarly, the C-terminal carboxyl function was derivatized as amide instead of esterification to avoid fast clearance rates due to hydrolysis of the esters by lipases. Moreover, N-alkyl and N-aryl amides were selected which are known to be more stable towards peptidases.
For the synthesis of the inhibitors classical procedures of organic synthesis were applied (2). Related L- and D-cystine derivatives of formula II were prepared according to standard procedures of peptide chemistry and then amidated with EDCIlHOBt according to Scheme 1. Subsequent reduction of the cystine compounds of formula III to the cysteine derivatives of Formula I was performed with reducing agents like mercaptanes or preferentially with phosphines like tributylphosphine, as shown in scheme 1.
______ _. __.__ _. _ ~_.~_ _ ~_ ~_ _._. T
R1~A/~ OH RmA/~ NHR
O
H EDCl'HCl S ~ HOBt S Bu P Rm /~ _ .R
+ 2 ~N-R --~ S Triflou hanol 95% 2 A
H
HS
/A~ OH /A~ NHR
O O
Scheme 1. General route for the synthesis of the MMP inhibitors of the present invention The compounds of the present invention, which specifically inhibit MMPs, are pharmacologically useful in the treatment of rheumatoid arthritis and related diseases in which collagenolytic activity is a contributing factor, such as, for example, corneal ulceration, osteoporosis, periodontitis, Paget's disease, gingivitis, tumor invasion, dystrophic epidermolysis, bullosa, systemic ulceration, epidermal ulceration, gastric ulceration, and the like. These compounds are particularly useful in the treatment of rheumatoid arthritis (primary chronic polyarthritis, PCP), systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis, Sjogren's syndrome (RA + sicca syndrome), polyarteritis nodosa and related vasculities, e. g. Wegener's granulomatosis, giant-cell arteritis, Goodpasture's syndrome, hypersensitiveness angiitis, polymyositis and dermatomyositis, progressive system sclerosis, M. Behcet, Reiter syndrome (arthtritis +
urethritis + conjunctivitis), mixed connective tissue disease (Sharp's syndrome), spondylitis ankylopoetica (M. Bechterew).
The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route and in dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art.
O
H EDCl'HCl S ~ HOBt S Bu P Rm /~ _ .R
+ 2 ~N-R --~ S Triflou hanol 95% 2 A
H
HS
/A~ OH /A~ NHR
O O
Scheme 1. General route for the synthesis of the MMP inhibitors of the present invention The compounds of the present invention, which specifically inhibit MMPs, are pharmacologically useful in the treatment of rheumatoid arthritis and related diseases in which collagenolytic activity is a contributing factor, such as, for example, corneal ulceration, osteoporosis, periodontitis, Paget's disease, gingivitis, tumor invasion, dystrophic epidermolysis, bullosa, systemic ulceration, epidermal ulceration, gastric ulceration, and the like. These compounds are particularly useful in the treatment of rheumatoid arthritis (primary chronic polyarthritis, PCP), systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis, Sjogren's syndrome (RA + sicca syndrome), polyarteritis nodosa and related vasculities, e. g. Wegener's granulomatosis, giant-cell arteritis, Goodpasture's syndrome, hypersensitiveness angiitis, polymyositis and dermatomyositis, progressive system sclerosis, M. Behcet, Reiter syndrome (arthtritis +
urethritis + conjunctivitis), mixed connective tissue disease (Sharp's syndrome), spondylitis ankylopoetica (M. Bechterew).
The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route and in dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art.
Accordingly, the invention provides a class of novel pharmaceutical compositions comprising one or more compounds of the present invention, in association with one or more non-toxic pharmaceutically acceptable carriers and/or adjuvants (collectively referred to herein as "carrier materials") and, if desired, other active ingredients. the compounds and compositions may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.
For all administrations, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit contained in a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. A
suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose from about 0.1 to 300 mg/kg body weight, particularly from about 1 to 30 mg/kg body weight may be appropriate. The active ingredient may also be administered by injection.
The dose regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical conditions of the patient.
Severity of the infection and the role of administration and the particular compound employed and thus may vary widely.
For therapeutic purposes, the compounds of the invention are ordinarily combined with one ore more adjuvants appropriate to the indicated route of administation. If per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl ester, talc, stearic acid, magnesium stearat, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, gelatine, acacia, sodium alginate, polyvinyl-pyrrolidone and/or polyvinyl alcohol, and thus tabletted or encapsulated for convenient administration. Alternatively, the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cotton seed oil, peanut oil, sesam oil, benryl alcohol, sodium chloride and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. Appropriate dosages in any given instance, of course, depend upon the nature and severity of the condition treated, the route of administration and the species of mammal involved, including its size and any individual idiosyncrasies.
Representative carriers, dilutions and adjuvants include, for example, water, lactose, gelatine starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene glycols, petroleum gelly, etc. The pharmaceutical compositions may be made up in a solid form, such as granules, powders or suppositories, or in liquid form, such as solutions, suspensions or emulsions. The pharmaceutical compositions may be subjected to conventional pharmaceutical adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.
For use in the treatment of rheumatoid arthritis, the compounds of this invention can be administered by any convenient route, preferably in the form of a pharmaceutical composition adpted to such route and in a dose effective for the intended treatment. In the treatment of arthritis, administration may be conveniently be by the oral route or by injection intra-articularly into the affected joint.
As indicated, the dose administered and the treatment regimen will be dependent, for example, on the disease, the severity thereof, on the patient being treated and his response to treatment and, therefore, may be widely varied.
Enzyme assay The catalytic domain of MMP8 (Phe'9-MMP8) and MMP3 were used for the inhibition experiments. Enzyme assays were performed at 25° C in 10 mM CaClz, 100 mM NaCI, 50 mM Tris/HCl {pH 7.6) using 8 nM enzyme concentrations and the fluorogenic substrates Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NHZ (Bachem M-1855, 1.10-5 M) for MMP8 and Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp~NH2 (Bachem M-2110, 4.10-6 M) for MMP3: Measurements were performed essentially as described by Stack et al. (3) for MIvv~8 and by Nagase et al. (4) for NiNIP3. The increase in fluorescence at 350 nm (~8) or 390 nm (M1VB~3) was monitored over a period of 100 sec to determine initial rates of hydrolysis. Evaluation of the kinetic data was performed as reported by Copeland et al. (5).
Table I. Examples for inhibition of HiIvIPB and M1VVIP3 with non-peptidic L-cysteine derivatives of the general formula I
Compound R,-A R K;; Mr~IPB I~; ~3 fpMl fNM1 10 I \ o~ ~ ~ 0.71 4.9 ,N
I
14 ~H, ~_~ s_ ~ ~ 1.0 9.7 ~ o~ I ~ 0.16 i2.3 i 15 Synthesis General methods:
A) Amidation: 1 mmole N,N'-urethanyl-cystine, 2 mmo! HOBT
(hydroxybenzotriazole) and 2.08 mmole EDCI (N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride) are dissolved or suspended in 10 ml THF. The amine is added in excess {2.5-5 mmoi) and in the case of the hydrochloride equivalent amounts of N-methylmorpholine are added. The reaction mixture is stirred overnight at room temperature, concentrated to a small volume and distributed between ethyl acetate and water. The organic layer is washed twice with 5 % NaHC03, 5 % KHS04 and water and dried over MgS04. The solvent is evaporated and the residue precipitated from ethyl acetate with suitable solvents like petroleum ether, diisopropylether, tert-butyl methyl ether or pentane.
B) Reduction: the cystine compound ( 1 mmol) is reacted in 10 ml 95 %
trifluorethanol with 1. S mmol tributylphosphine. The reaction mixture is stirred overnight at room temperature, evaporated to small volume and upon dilution with ethyl acetate the product is precipitated with suitable solvents like petroleum ether, diisopropylether, tert-butyl methyl ether or pentane.
i 5 N,N'-Bis-benryloxycarbonyl-L-cystine-bis-hydrox~amate (Sa) Prepared from N,N'-bis-benzyloxycarbonyl-L-cystine (2) and hydroxylamine according to procedure (A). Yield: 22 %; homogeneous on TLC (solvent system:
chloroform/methanol; 4 : 1, Rf= 0.5).
FAB-MS: m/z = 539.2 [M+H+]; Mf= 538.2 calculated for C2=H26N4OgS2 Berrryloxycarborryl-L-cysteine-hydroxamate (S) Prepared according to procedure (B) from Sa. Purified by flash chromatography (eluent:
CHZC12/MeOH, 95:5 followed by 45:5). Yield: 18 %.
'H-NMR (d6-DMSO): 10.7 (bs, 1H, NHOH); 8.89 (bs, 1H, OH); 7.50 (d, 1H, NH
ureth.); 7.38 (m, SH, arom. H's); 5.03 (s, 2H, CH2 v. Z); 3.99 (m, IH, H-C(a));
2.75/2.66 (2xm, 2H, ~i-CH2); 2.29 (bs, 1H, SH).
Bis-tert-butyloxycarbonyl-L-cystine-bis-bensylamide (6a) Prepared from N,N'-bis-tert-butyloxycarbonyl-L-cystine ( 12) and benzylamine according to (A). Yield: 77 %. Homogeneous on TLC (solvent system:
cyclohexane/chloroform/acetic acid, 45:45:10, Rf = 0.7).
L-Cystine-bis-benrylamide hydrochloride (6b) 13.87 g (22.4 mmol) 6a in 100 ml 4.6 M HCl in dioxane was stirred overnight at room temperature: The precipitate was collected and washed extensively with ether.
Yield: 11 g (quantitative).
N,N =Bis~rcetyl-L-cystine-bis benzylamide (6c) 300 mg (0.61 mmol) 6b was distributed between ethyl acetate and 40 ml NaHC03 (5 %) and then reacted with acetic anhydride (0.27 g, 2.6 mmol). The organic layer was washed with water, dried over MgSOa and evaporated to dryness. Yield: 94 %;
homogeneous on TLC (solvent system: cyclohexane/chloroform/acetic acid:
45:45:10, Rf = 0.4).
N Acetyl L-cysteirre-berrrylamide (6) 6c was reduced according to procedure (B). Yield: 65 %; homogeneous on TLC
(solvent system: CHCI3MIeOH; 4 : 1, Rr= 0.7); m.p. 186 - 189 °C;
'H-NMR (d6-DMSO): 8.56 (t, 1H, NH, amide); 8.23 (d, 1H, NH ureth.); 7.32-7.09 (m, SH, arom. H's); 4.56, or 4.38 (m, 1H, H-CQ ); 4.28 (m, 2H, CH2-Bn); 3.12/2.89, oder 2.79/2.69 (2xm, 2H, ~i-CHZ); 2.30 (bs, 1H, SH); 1.87 (d, 3H, CH3).
FAB-MS: m/z = 253.1 [M+H+]; M~= 252.1 calculated for C12H~6N2O2S
N,N -Bis formyl-L-cysti»e-bis-benrylamide (7a) Prepared from 6b and formic acid according to procedure (A}. Yield: 59 %;
homogeneous on TLC (solvent system: cyclohexane/CHCi3/acetic acid, 45:45:10;
Rr =
0.1).
N Formyl-L-cysteine-benrylamide (7) Reduction of 7a according to procedure (B). Yield: 62 %; homogeneous on TLC
(solvent system: cyclohexane/CHCl3/acetic acid; 45:45:10; Rf = 0.45); m.p. 180 °C.
'H-NMR (d6-DMSO): 8.58 (t, 1H, NH, amide); 8.35 (d, 1H, NH ureth.); 8.10 (s, 1H, formyl-H); 7.33-7.21 (m, 5H, atom. H's); 4.49, (m, 1H, H-Ca ); 4.30 (d, 2H, CHZ-Bn);
2.82/2.72 (2xm, 2H, ~i-CH2); 2.26 (bs, 1H, SH).
FAB-MS: m/z = 239.0 [M+H+]; Ivi~= 238.3 calculated for C"H,4NZOZS
tert-Butyloxycarborryl-L-cysteine-berrzylamide (8) Reduction of 6a according to procedure (B). Yield: 38 %; homogeneous on TLC
(solvent system: heptanelt-butanoUacetic acid 5:1:1, Rf= 0.7); m.p. 97 - 100 °C;
'H-NMR (d6-DMSO): 8.38 (m, 1H, NH, amide); 7.32-7.21 (m, 5H, atom. H's); 6.95 (d, 1H, NH-ureth.); 4.29 (d, 2H, CH2-Bn); 4.08 (m, 1H, H-Ca ); 2.81/2.68 (2xm, 2H, ~3-CH2); 2.29 (bs, 1H, SH); 1.40 (s, 9H, t-Bu).
FAB-MS: m/z = 311.1 [M+H+]; Mt= 310.1 calculated for C,sHZZN203S
N,N =Bis-benzyloxycarborryl-L-cystine-bis-benzylamide (9a) From N,N'-bis-benzyloxycarbonyl-cystine and benzylamine according to (A).
Yield: 90 N Benzyloxycarbonyl-L-cysteine-benzylamide (9) Reduction of 9a according to (B). Yield: 41 %; homogeneous on TLC (solvent system:
cyclohexaneJCHCI~/acetic acid, 45:45:10, Rf= 0.4); m.p. 148 - 152 °C;
. 'H-NMR (d6-DMSO): 8.50 (m, 1H, NH, amide); 7.49 (d, 1H, NH ureth.); 7.37-7.23 (m, IOH, atom.. H's); 5.06 (dd, 2H, CH2 v. Z); 4.30 (d, 2H, CHZ-Bn); 4.16 (m, 1H, H-Ca );
2.84/2.70 (2xm, 2H, ~i-CH2); 2.33 (bs, 1H, SH).
FAB-MS: m/z = 345.0 [M+H+]; Mr= 344.4 calculated for C'8H2oN203S
N,N'-Bis-benryloxycarbonyl-L-cystine-bis-4 pyridylmethylamide (l0a) From N,N'-bis-benzyloxycarbonyl-L-cystine and 4-(aminomethyl)pyridine according to procedure (A). Yield. 59 %; homogeneous on TLC (solvent system: CHCIs/MeOH, 4:1, Rr= 0.65).
N Benryloxycarbonyl-L-cysteine-4 pyridylmethylamide (10) From l0a according to procedure (B). Yield: 65 %; homogeneous on TLC (solvent system: CHCI3/MeOH, 4:1, Rf= 0.8); m.p. 122 - 125 °C;
'H-NMR (d6-DMSO): 8.61 (t, 1H, NH, amide); 8.48/7.37/7.25 (m, respectively, 9H, arom. H's); 7.56 (d, 1H, NH-ureth.); 5.08 (dd, 2H, CHz, Z}; 4.32 (d, 2H, CHZ-Bn); 4.18 (m, 1H, H-Ca ); 2.87/2.72 (2xm, 2H, ~i-CHZ); 2.40 (bs, 1H, SH).
FAB-MS: m/z = 346.2 [M+H+]; Mf= 345.1 calculated for C,~H,9N3O3S
N,N =Bis benzyloxycarbonyl L-cystine-bis-3 pyridylmethylamide (ll a) From N,N'-bis-benzyloxycarbonyl-cystine and 3-(aminomethyl)pyridine according to procedure (A). Yield: 69 %; homogeneous on TLC (solvent system: CHCI3/MeOH, 4:1, Rr= 0.2).
N Benryloxycarborryl-L-cysteine-3 pyridylmethylamide (ll) Reduction of lla according to procedure (B). Yield: 14 %; homogeneous on TLC
(solvent system: CHCI3lMeOH, 4:1, Rf= 0.8); m.p. 125 - 127 °C;
1H-NMR (d6-DMSO): 8.58 (t, 1H, NH, amide); 8.50/8.45/7.65/7.36 (m, respectively, 9H, arom. H's); 7.52 (d, 1H, NH-ureth.); 5.07 (dd, 2H, CHz v. Z); 4.42 (d, 2H, CHZ-Bn); 4.15 (m, 1H, H-CQ ); 2.82/2.?1 (2xm, 2H, ~i-CH2}; 2.36 (bs, 1H, SH).
FAB-MS: m/z = 346.1 [M+H+]; Mf= 345.1 calculated for C,7H,gN;O;S
N,N'-Bis-berrryloxycarbonyl-L-cystirte-bis-2 pyridylmethylamide (12a) From N,N'-bis-benzyloxycarbonyl-cystine and 2-(aminomethyl)pyridine according to (A). Yield: 96 %; homogeneous on TLC (solvent system: CHCl3/MeOH, 4:1, Rf=
0.7).
N Benryloxycarborryl L-cysteine-2 pyridylmethylamide (12) Reduction of 12a according to (B). Yield: 33 %; homogeneous on TLC (solvent system:
CHC13/MeOH, 4:1, Rf= 0.8); m.p. 129 - 131 °C;
'H-NMR (d6-DMSO): 8.59 (t, 1H, NH, amide); 8.48/7.72/7.36-7.22 (m,respectively, 9H, arom. H's); 7.52 (d, IH, NH-ureth.); 5.07 (dd, 2H, CHZ v. Z); 4.49 (d, 2H, CHZ-S Bn); 4.20 (m, 1H, H-CQ ); 2.85/2.72 (2xm, 2H, ~i-CH2); 2.42 (bs, 1H, SH).
FAB-MS: m/z = 346.1 [M+H+]; Mf= 345.1 calculated far C,~H19N3O3S
N,N =Bis-benzoyl L-cystine-bis-benrylamide (13a) 10 From 6b and benzoic acid according to (A). Yield: 78 %; homogeneous on TLC
(solvent system: cyclohexane/CHCI~/acetic acid; 45:45:10, Rr= 0.65).
N Be~uoyl L-cysteine-benrylamide (13) By reduction of 13a according to (B). Yield: 57 %; homogeneous on TLC (solvent 15 system: cyclohexanelCHCI~/acetic acid; 45:45:10, Rf= 0.55); m.p. 174 - 176 °C;
1H-NMR {d6-DMSO): 8.56 (t, 1H, NH, amide); 7.92 {d, 1H, NH ureth.); 7.57-7.22 (m, lOH, arom. H's); 4.59, (m, 1H, H-CQ ); 4.31 (d, 2H, CH2-Bn); 2.98/2.89 (2xm, 2H, (i-CH2); 2.41 (t, 1H, SH).
FAB-MS: m/z = 315.1 [M+H+]; Mf= 314.1 calculated for C,~H~8N202S
N,N'-Bis-tosyl L-cystine-bis-benzylamide (14a) 390 mg (0.794 mmol) 6b were reacted with 180 mg (0.952 mmol) tosyl chloride in 6 ml pyridine. After 12 h stirring at room temperature the solid was filtered off and the filtrate evaporated to dryness adding toluene and finally tent-butyl methyl ether.
Yield: 81 %;
homogeneous on TLC (solvent system: CHCI3/MeOH, 4:1, Rf= 0.7).
N Tosyl L-cystei»e-benzylamide (14) By reduction of 14a according to (B). Yield: 54 %; homogeneous on TLC (solvent system: CHC13/MeOH, 4:1, Rf= 0.6); m.p. 180 - 182 °C;
For all administrations, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit contained in a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. A
suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose from about 0.1 to 300 mg/kg body weight, particularly from about 1 to 30 mg/kg body weight may be appropriate. The active ingredient may also be administered by injection.
The dose regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical conditions of the patient.
Severity of the infection and the role of administration and the particular compound employed and thus may vary widely.
For therapeutic purposes, the compounds of the invention are ordinarily combined with one ore more adjuvants appropriate to the indicated route of administation. If per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl ester, talc, stearic acid, magnesium stearat, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, gelatine, acacia, sodium alginate, polyvinyl-pyrrolidone and/or polyvinyl alcohol, and thus tabletted or encapsulated for convenient administration. Alternatively, the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cotton seed oil, peanut oil, sesam oil, benryl alcohol, sodium chloride and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. Appropriate dosages in any given instance, of course, depend upon the nature and severity of the condition treated, the route of administration and the species of mammal involved, including its size and any individual idiosyncrasies.
Representative carriers, dilutions and adjuvants include, for example, water, lactose, gelatine starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene glycols, petroleum gelly, etc. The pharmaceutical compositions may be made up in a solid form, such as granules, powders or suppositories, or in liquid form, such as solutions, suspensions or emulsions. The pharmaceutical compositions may be subjected to conventional pharmaceutical adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.
For use in the treatment of rheumatoid arthritis, the compounds of this invention can be administered by any convenient route, preferably in the form of a pharmaceutical composition adpted to such route and in a dose effective for the intended treatment. In the treatment of arthritis, administration may be conveniently be by the oral route or by injection intra-articularly into the affected joint.
As indicated, the dose administered and the treatment regimen will be dependent, for example, on the disease, the severity thereof, on the patient being treated and his response to treatment and, therefore, may be widely varied.
Enzyme assay The catalytic domain of MMP8 (Phe'9-MMP8) and MMP3 were used for the inhibition experiments. Enzyme assays were performed at 25° C in 10 mM CaClz, 100 mM NaCI, 50 mM Tris/HCl {pH 7.6) using 8 nM enzyme concentrations and the fluorogenic substrates Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NHZ (Bachem M-1855, 1.10-5 M) for MMP8 and Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp~NH2 (Bachem M-2110, 4.10-6 M) for MMP3: Measurements were performed essentially as described by Stack et al. (3) for MIvv~8 and by Nagase et al. (4) for NiNIP3. The increase in fluorescence at 350 nm (~8) or 390 nm (M1VB~3) was monitored over a period of 100 sec to determine initial rates of hydrolysis. Evaluation of the kinetic data was performed as reported by Copeland et al. (5).
Table I. Examples for inhibition of HiIvIPB and M1VVIP3 with non-peptidic L-cysteine derivatives of the general formula I
Compound R,-A R K;; Mr~IPB I~; ~3 fpMl fNM1 10 I \ o~ ~ ~ 0.71 4.9 ,N
I
14 ~H, ~_~ s_ ~ ~ 1.0 9.7 ~ o~ I ~ 0.16 i2.3 i 15 Synthesis General methods:
A) Amidation: 1 mmole N,N'-urethanyl-cystine, 2 mmo! HOBT
(hydroxybenzotriazole) and 2.08 mmole EDCI (N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride) are dissolved or suspended in 10 ml THF. The amine is added in excess {2.5-5 mmoi) and in the case of the hydrochloride equivalent amounts of N-methylmorpholine are added. The reaction mixture is stirred overnight at room temperature, concentrated to a small volume and distributed between ethyl acetate and water. The organic layer is washed twice with 5 % NaHC03, 5 % KHS04 and water and dried over MgS04. The solvent is evaporated and the residue precipitated from ethyl acetate with suitable solvents like petroleum ether, diisopropylether, tert-butyl methyl ether or pentane.
B) Reduction: the cystine compound ( 1 mmol) is reacted in 10 ml 95 %
trifluorethanol with 1. S mmol tributylphosphine. The reaction mixture is stirred overnight at room temperature, evaporated to small volume and upon dilution with ethyl acetate the product is precipitated with suitable solvents like petroleum ether, diisopropylether, tert-butyl methyl ether or pentane.
i 5 N,N'-Bis-benryloxycarbonyl-L-cystine-bis-hydrox~amate (Sa) Prepared from N,N'-bis-benzyloxycarbonyl-L-cystine (2) and hydroxylamine according to procedure (A). Yield: 22 %; homogeneous on TLC (solvent system:
chloroform/methanol; 4 : 1, Rf= 0.5).
FAB-MS: m/z = 539.2 [M+H+]; Mf= 538.2 calculated for C2=H26N4OgS2 Berrryloxycarborryl-L-cysteine-hydroxamate (S) Prepared according to procedure (B) from Sa. Purified by flash chromatography (eluent:
CHZC12/MeOH, 95:5 followed by 45:5). Yield: 18 %.
'H-NMR (d6-DMSO): 10.7 (bs, 1H, NHOH); 8.89 (bs, 1H, OH); 7.50 (d, 1H, NH
ureth.); 7.38 (m, SH, arom. H's); 5.03 (s, 2H, CH2 v. Z); 3.99 (m, IH, H-C(a));
2.75/2.66 (2xm, 2H, ~i-CH2); 2.29 (bs, 1H, SH).
Bis-tert-butyloxycarbonyl-L-cystine-bis-bensylamide (6a) Prepared from N,N'-bis-tert-butyloxycarbonyl-L-cystine ( 12) and benzylamine according to (A). Yield: 77 %. Homogeneous on TLC (solvent system:
cyclohexane/chloroform/acetic acid, 45:45:10, Rf = 0.7).
L-Cystine-bis-benrylamide hydrochloride (6b) 13.87 g (22.4 mmol) 6a in 100 ml 4.6 M HCl in dioxane was stirred overnight at room temperature: The precipitate was collected and washed extensively with ether.
Yield: 11 g (quantitative).
N,N =Bis~rcetyl-L-cystine-bis benzylamide (6c) 300 mg (0.61 mmol) 6b was distributed between ethyl acetate and 40 ml NaHC03 (5 %) and then reacted with acetic anhydride (0.27 g, 2.6 mmol). The organic layer was washed with water, dried over MgSOa and evaporated to dryness. Yield: 94 %;
homogeneous on TLC (solvent system: cyclohexane/chloroform/acetic acid:
45:45:10, Rf = 0.4).
N Acetyl L-cysteirre-berrrylamide (6) 6c was reduced according to procedure (B). Yield: 65 %; homogeneous on TLC
(solvent system: CHCI3MIeOH; 4 : 1, Rr= 0.7); m.p. 186 - 189 °C;
'H-NMR (d6-DMSO): 8.56 (t, 1H, NH, amide); 8.23 (d, 1H, NH ureth.); 7.32-7.09 (m, SH, arom. H's); 4.56, or 4.38 (m, 1H, H-CQ ); 4.28 (m, 2H, CH2-Bn); 3.12/2.89, oder 2.79/2.69 (2xm, 2H, ~i-CHZ); 2.30 (bs, 1H, SH); 1.87 (d, 3H, CH3).
FAB-MS: m/z = 253.1 [M+H+]; M~= 252.1 calculated for C12H~6N2O2S
N,N -Bis formyl-L-cysti»e-bis-benrylamide (7a) Prepared from 6b and formic acid according to procedure (A}. Yield: 59 %;
homogeneous on TLC (solvent system: cyclohexane/CHCi3/acetic acid, 45:45:10;
Rr =
0.1).
N Formyl-L-cysteine-benrylamide (7) Reduction of 7a according to procedure (B). Yield: 62 %; homogeneous on TLC
(solvent system: cyclohexane/CHCl3/acetic acid; 45:45:10; Rf = 0.45); m.p. 180 °C.
'H-NMR (d6-DMSO): 8.58 (t, 1H, NH, amide); 8.35 (d, 1H, NH ureth.); 8.10 (s, 1H, formyl-H); 7.33-7.21 (m, 5H, atom. H's); 4.49, (m, 1H, H-Ca ); 4.30 (d, 2H, CHZ-Bn);
2.82/2.72 (2xm, 2H, ~i-CH2); 2.26 (bs, 1H, SH).
FAB-MS: m/z = 239.0 [M+H+]; Ivi~= 238.3 calculated for C"H,4NZOZS
tert-Butyloxycarborryl-L-cysteine-berrzylamide (8) Reduction of 6a according to procedure (B). Yield: 38 %; homogeneous on TLC
(solvent system: heptanelt-butanoUacetic acid 5:1:1, Rf= 0.7); m.p. 97 - 100 °C;
'H-NMR (d6-DMSO): 8.38 (m, 1H, NH, amide); 7.32-7.21 (m, 5H, atom. H's); 6.95 (d, 1H, NH-ureth.); 4.29 (d, 2H, CH2-Bn); 4.08 (m, 1H, H-Ca ); 2.81/2.68 (2xm, 2H, ~3-CH2); 2.29 (bs, 1H, SH); 1.40 (s, 9H, t-Bu).
FAB-MS: m/z = 311.1 [M+H+]; Mt= 310.1 calculated for C,sHZZN203S
N,N =Bis-benzyloxycarborryl-L-cystine-bis-benzylamide (9a) From N,N'-bis-benzyloxycarbonyl-cystine and benzylamine according to (A).
Yield: 90 N Benzyloxycarbonyl-L-cysteine-benzylamide (9) Reduction of 9a according to (B). Yield: 41 %; homogeneous on TLC (solvent system:
cyclohexaneJCHCI~/acetic acid, 45:45:10, Rf= 0.4); m.p. 148 - 152 °C;
. 'H-NMR (d6-DMSO): 8.50 (m, 1H, NH, amide); 7.49 (d, 1H, NH ureth.); 7.37-7.23 (m, IOH, atom.. H's); 5.06 (dd, 2H, CH2 v. Z); 4.30 (d, 2H, CHZ-Bn); 4.16 (m, 1H, H-Ca );
2.84/2.70 (2xm, 2H, ~i-CH2); 2.33 (bs, 1H, SH).
FAB-MS: m/z = 345.0 [M+H+]; Mr= 344.4 calculated for C'8H2oN203S
N,N'-Bis-benryloxycarbonyl-L-cystine-bis-4 pyridylmethylamide (l0a) From N,N'-bis-benzyloxycarbonyl-L-cystine and 4-(aminomethyl)pyridine according to procedure (A). Yield. 59 %; homogeneous on TLC (solvent system: CHCIs/MeOH, 4:1, Rr= 0.65).
N Benryloxycarbonyl-L-cysteine-4 pyridylmethylamide (10) From l0a according to procedure (B). Yield: 65 %; homogeneous on TLC (solvent system: CHCI3/MeOH, 4:1, Rf= 0.8); m.p. 122 - 125 °C;
'H-NMR (d6-DMSO): 8.61 (t, 1H, NH, amide); 8.48/7.37/7.25 (m, respectively, 9H, arom. H's); 7.56 (d, 1H, NH-ureth.); 5.08 (dd, 2H, CHz, Z}; 4.32 (d, 2H, CHZ-Bn); 4.18 (m, 1H, H-Ca ); 2.87/2.72 (2xm, 2H, ~i-CHZ); 2.40 (bs, 1H, SH).
FAB-MS: m/z = 346.2 [M+H+]; Mf= 345.1 calculated for C,~H,9N3O3S
N,N =Bis benzyloxycarbonyl L-cystine-bis-3 pyridylmethylamide (ll a) From N,N'-bis-benzyloxycarbonyl-cystine and 3-(aminomethyl)pyridine according to procedure (A). Yield: 69 %; homogeneous on TLC (solvent system: CHCI3/MeOH, 4:1, Rr= 0.2).
N Benryloxycarborryl-L-cysteine-3 pyridylmethylamide (ll) Reduction of lla according to procedure (B). Yield: 14 %; homogeneous on TLC
(solvent system: CHCI3lMeOH, 4:1, Rf= 0.8); m.p. 125 - 127 °C;
1H-NMR (d6-DMSO): 8.58 (t, 1H, NH, amide); 8.50/8.45/7.65/7.36 (m, respectively, 9H, arom. H's); 7.52 (d, 1H, NH-ureth.); 5.07 (dd, 2H, CHz v. Z); 4.42 (d, 2H, CHZ-Bn); 4.15 (m, 1H, H-CQ ); 2.82/2.?1 (2xm, 2H, ~i-CH2}; 2.36 (bs, 1H, SH).
FAB-MS: m/z = 346.1 [M+H+]; Mf= 345.1 calculated for C,7H,gN;O;S
N,N'-Bis-berrryloxycarbonyl-L-cystirte-bis-2 pyridylmethylamide (12a) From N,N'-bis-benzyloxycarbonyl-cystine and 2-(aminomethyl)pyridine according to (A). Yield: 96 %; homogeneous on TLC (solvent system: CHCl3/MeOH, 4:1, Rf=
0.7).
N Benryloxycarborryl L-cysteine-2 pyridylmethylamide (12) Reduction of 12a according to (B). Yield: 33 %; homogeneous on TLC (solvent system:
CHC13/MeOH, 4:1, Rf= 0.8); m.p. 129 - 131 °C;
'H-NMR (d6-DMSO): 8.59 (t, 1H, NH, amide); 8.48/7.72/7.36-7.22 (m,respectively, 9H, arom. H's); 7.52 (d, IH, NH-ureth.); 5.07 (dd, 2H, CHZ v. Z); 4.49 (d, 2H, CHZ-S Bn); 4.20 (m, 1H, H-CQ ); 2.85/2.72 (2xm, 2H, ~i-CH2); 2.42 (bs, 1H, SH).
FAB-MS: m/z = 346.1 [M+H+]; Mf= 345.1 calculated far C,~H19N3O3S
N,N =Bis-benzoyl L-cystine-bis-benrylamide (13a) 10 From 6b and benzoic acid according to (A). Yield: 78 %; homogeneous on TLC
(solvent system: cyclohexane/CHCI~/acetic acid; 45:45:10, Rr= 0.65).
N Be~uoyl L-cysteine-benrylamide (13) By reduction of 13a according to (B). Yield: 57 %; homogeneous on TLC (solvent 15 system: cyclohexanelCHCI~/acetic acid; 45:45:10, Rf= 0.55); m.p. 174 - 176 °C;
1H-NMR {d6-DMSO): 8.56 (t, 1H, NH, amide); 7.92 {d, 1H, NH ureth.); 7.57-7.22 (m, lOH, arom. H's); 4.59, (m, 1H, H-CQ ); 4.31 (d, 2H, CH2-Bn); 2.98/2.89 (2xm, 2H, (i-CH2); 2.41 (t, 1H, SH).
FAB-MS: m/z = 315.1 [M+H+]; Mf= 314.1 calculated for C,~H~8N202S
N,N'-Bis-tosyl L-cystine-bis-benzylamide (14a) 390 mg (0.794 mmol) 6b were reacted with 180 mg (0.952 mmol) tosyl chloride in 6 ml pyridine. After 12 h stirring at room temperature the solid was filtered off and the filtrate evaporated to dryness adding toluene and finally tent-butyl methyl ether.
Yield: 81 %;
homogeneous on TLC (solvent system: CHCI3/MeOH, 4:1, Rf= 0.7).
N Tosyl L-cystei»e-benzylamide (14) By reduction of 14a according to (B). Yield: 54 %; homogeneous on TLC (solvent system: CHC13/MeOH, 4:1, Rf= 0.6); m.p. 180 - 182 °C;
'H-NMR (d6-DMSO): 8.41 (t, 1H, NH, amide); 7.98/7.68/7.35-7.14 (m, respectively, and d's, IOH, arom. H's, NH ureth.); 4.13 (d, 2H, CHZ-Bn); 3.86 (m, 1H, H-Ca);
2.59 (m, 2H, [i-CH2); 2.38 (s, 3H, CH3); 2.17 (t, 1H, SH).
FAB-MS: m/z = 365.1 [M+H']; Mr= 364.1 calculated for C,~HZON203S
N,N'-Bis-benryloxycarbonyl L-cystine-bis-2 phenylethylamide (1 Sa) From N,N'-bis-benzyloxycarbonyl-L-cystine and 2-phenylethylamine according to (A).
Yield: 34 %; homogeneous on TLC (solvent system: CHC13/MeOH, 19:1, Rf= 0.8).
N Benryloxycarbonyl-L-cysteine-2 phenylethylamide (1 S) Reduction of 15a according to (B). Yield: 61 %; homogeneous on TLC (solvent system:
cyclohexane/CHCl3/acetic acid, 45:45:10, Rr= 0.6); m.p. 119 - 121 °C;
'H-NMR (d6-DMSO): 8.02 (t, 1H, NH, amide); 7.39-7.18 (m, 11H, arom. H's, NH
ureth.); 5.03 (dd, 2H, CH2 v. Z); 4.06 (m, 1H, H-Ca ); 2.72/2.61 (2xm, 4H, CHz-CH2);
2.22 (bs, 1H, SH).
FAB-MS: m/z = 359.1 [M+H+];1VI<= 358.1 calculated for C'9HzZN2O3S
N,N'-Bis-benryloxycarbonyl-L-cystine-bis-2-(4-hydroxyphenyl)ethylamide (16a) From N,N'-bis-benzyloxycarbonyl-cystine and 2-(4-hydroxyphenyl)ethylamine according to (A). Yield: 71 %; homogeneous on TLC (solvent system:
cyclohexane/CHC13/acetic acid, 45:45:10, Rf= 0.5).
N Benryloxycarbonyl-L-cysteine-2-(4-hydroxyphenyl)ethylamid (16) Reduction of 16a according to (B). Yield: 24 %; homogeneous on TLC (solvent system:
cyciohexane/CHCl3/acetic acid, 45:45:10, R~= 0.6); m.p. 133 - 135 °C;
1H-NMR {d6-DMSO): 9.11 (s, 1H, phenol. OH); 7.98 (t, 1H, NH, amide); 7.38 (m, 6H, arom. v. Z, NH ureth.); 6.99/6.68 (2xd, 4H, arom., phenol. H's); 5.04 (dd, 2H, CH2 v.
Z); 4.05 (m, 1H, H-CQ ); 2.73/2.60 (2xm, 4H, CH2-CH2); 2.26 (bs, 1H, SH).
FAB-MS: m/z = 375.2 [M+H+]; Mr= 374.1 calculated for C'9H22NZO4S
N,N'-Bis-benryloxycarbonyl-L-cystine-bis-.f-chlorobenrylamide (17a) T.____~ _ _._____ _ __ ._.___.
i7 From N,N'-bis-benzyloxycarbonyl-cystine and 4-chlorobenzylamine according to (A).
Yield: 99 %; homogeneous on TLC (solvent system: CHCl3/MeOH, 19:1, Rf= 0.8) N Benryloxycarbonyl-L-cysteine-4-chlorobenrylamide (17) Reduction of 17a according to (B). Yield: 71 %; homogeneous on TLC (solvent system:
cyclohexane/CHC13/acetic acid, 45:45:10, Rr= 0.85); m.p. 137 - 139 °C;
1H-NMR (d6-DMSO): 8.53 (t, 1H, NH, amide); 7.51 (d, 1H, NH ureth.); 7.38-7.26 (m, 9H, arom.. H's); 5.06 (dd, 2H, CH2 v. Z); 4.29 (d, 2H, CH2-Bn); 4.13 (m, 1H, H-Ca );
2.82/2.70 (2xm, 2H, (3-CHZ); 2.53 (bs, 1H, SH).
FAB-MS: m/z = 379.1 [M+H+]; Mf= 378.1 calculated for C,8H19C1N203S
N,N=Bis-benryloxycarborryl L-cystine-bis-3 phenylpropylamide (18a) From N,N'-bis-benzyloxycarbonyi-cystine and 3-phenylpropylamine according to (A).
Yield: 94 %; homogeneous on TLC (solvent system: cyclohexanelCHCl3/acetic acid, 1 S 45:45:10, Rf = 0.7).
N Benryloxycarbonyl L-cysteine-3 phenylpropylamide (18) By reduction of 18a according to (B). Yield: 76 %; homogeneous on TLC (solvent system: cyclohexane/CHCh/acetic acid, 45:45:10, Rf= 0.7); m.p. 104 - 106 °C;
'H-NMR (d6-DMSO): 8.02 (t, 1H, NH, amide); 7.43 (d, 1H, NH ureth.); 7.38-7.15 (m, IOH, arom.. H's); 5.05 (dd, 2H, CH2 v. Z); 4.09 (m, 1H, H-CQ ); 3.12 (m, 2H, N-CHZ);
2.70/2.69 (2xm, 2H, ~3-CH2); 2.58 (t, 2H, CH2-Ph); 2.32 (bs, 1H, SH); 1.70 (m, 2H, CHZ.-CH2-CHZ).
FAB-MS: m/z = 373.2 [M+H+]; Mf= 372.2 calculated for C2oH24N203S
N,N' Bis-benryloxycarbonyl L-cystine-bis-tryptamide (19a) From N,N'-bis-benzyloxycarbonyl-cystine and tryptamine according to (A).
Yield: 75 %;
homogeneous on TLC (solvent system: cyclohexane/CHCl3/acetic acid, 45:45:10, Rf =
0.6).
Benryloxycarbonyl-L-cysteine-tryptamide (19) Reduction of 19a according to (B): Yield: 62 %; homogeneous on TLC (solvent system:
cyclohexane/CHCh/acetic acid, 45:45:10, Rf= 0.7); m.p. I50 - 152 °C;
'H-NMR (d6-DMSO): 10.80 (s, 1H, NH-tryptamine); 8.09 (t, IH, NH amide); 7.54 -6.96 (m, I1H, arom. H's, ureth. NH); 5.05 (dd, 2H, CHZ v. Z); 4.08 (m, 1H, H-C(cc));
3.32 (m, 2H, NHCH~CHz); 2.82 (t, 2H, NHCHZCH2); 2.77/2.65 (2xm, 2H, ~3-CH2);
2.26 (m, 1H, SH).
FAB-MS: m/z = 398.2 [M+H+]; Mf= 397.2 calculated for C21Hz3NsOsS
N,N'-Bis-hexanoyl-L-cystine-bis-benrylamide (20a) Prepared from 6b and hexanoic acid according to procedure (A). Yield: 86 %;
homogeneous on TLC (solvent system: cyclohexane/chloroform/acetic acid, 45:45:10; Rf = 0.6).
'H-NMR (d6-DMSO): 8.48 (t, 1H, NH, amide); 8.02 (d, 1H, NH-ureth.); 7.3-7.2 (m, SH, arom.. H's); 4.41 (m, 1H, H-Ca ); 4.28 (d, 2H, CH2-Bn); 2.80/2.70 (2xm, 2H, (3-i 5 CH2); 2.25 (t, I H, SH); 2.17 (m, 2H, -CHrCO-); 1.49-1.21 (m, 1 OH, alkyl), 0.87 (t, 3H, _CH3).
N Hexanoyl L-cysteine-benrylamide (20) Reduction of 20a according to procedure (B). Yield: 69 %; m.p. 141 - 143 °C;
'H-NMR (d6-DMSO): 'H-NMR (d6-DMSO): 8.48 (t, 1H, NH, amide); 8.02 (d, 1H, NH-ureth.); 7.31-7.2 (m, SH, arom.. H's); 4.40 (m, IH, H-Ca ); 4.22 (d, 2H, CH2-Bn);
2.80/2.70 (2xm, 2H, (3-CH2); 2.3 (bs, 1H, SH); 2.12 (m, 2H, -CHI-CO-); 1.50-1.19 {m, 6H, alkyl), 0.85 (t, 3H, -CH3).
FAB-MS: m/z = 309.2 [M+H+]; Mr= 308.2 calculated for C,6Fi24N2O2S
N,N =Bis-octanoyl-L-cystine-bis-benrylamide (21 a) Prepared from 6b and octanoic acid according to procedure (A). Yield: 86 %;
homogeneous on TLC (solvent system: cyclohexanelchloroform/acetic acid, 45:45:10; Rf = 0.6).
N-0ctanoyl-L-cysteine-benrylamide (21) Reduction of 21a according to procedure (B). Yield: 73 %; m.p. 137 - 139 °C;
__.___ T ___ _ __. _ ._____ _____._T_ ~H-NMR (d6-DMSO): 1H-NMR (d6-DMSO): 8.48 (t, 1H, NH, amide); 8.02 (d, IH, NH-ureth.); 7.3-?.2 (m, SH, atom.. H's); 4.41 (m, 1H, H-CQ ); 4.28 (d, 2H, CH2-Bn);
2.80/2.70 (2xm, 2H, ~i-CH2); 2.25 (t, 1H, SH); 2.17 (m, 2H, -CHz-CO-); 1.49-I.21 (m, IOH, alkyl), 0.87 (t, 3H, -CH3).
S FAB-MS: m/z = 337.2 [M+H+]; Mr= 336.2 calculated for C,gH2gN2OZS
N,N' Bis~decanoyl-L-cystine-bis-benrylamide (ZZa) Prepared from 6b and decanoic acid according to procedure (A). Yield:
quantitative;
homogeneous on TLC (solvent system: cyclohexane/chloroform/acetic acid, 45:45:10; Rf = 0.9).
N Decanoic-L-cysteine-benrylamide (ZZ) Reduction of 22a according to procedure (B). Yield: 33 %; Rf= 0.7); m.p. 138 -140 °C;
'H-NMR (d6-DMSO): 8.46 (t, 1H, NH, amide); 8.02 (d, 1H, NH-ureth.); 7.3-7.2 (m, SH, atom.. H's); 4.4 (m, IH, H-CQ ); 4.29 (d, 2H, CHZ-Bn); 2.80/2.70 (2xm, 2H, [i-CHZ); 2.25 (t, 1H, SH); 2.18 (m, 2H, -CH2-CO-); 1.49-1.19 (m, 14H, alkyl), 0.85 (t, 3H, _CH3).
FAB-MS: m/z = 365.2 [M+H+]; M~= 364.2 calculated for C2d-i32N202S
1. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M.
Drug Disc. Today 1996 2. Wiinsch, E. in Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/I, Springer Verlag, Stuttgart, 1974.
3. Stack, M. S.; Gray, R. D. J. Bio1 Chem. 1989, 264, 4277.
4. Nagase, H.; Fields, C. G.; Fields, G. B. J. Biol. Chem. 1994, 269, 20952.
S. Copeland, R. A.; Lombardo, D.; Giannaras, J.; Decicco, C. P. Bioorg. Med Chem.
Lett. 1995, 5, 1947.
2.59 (m, 2H, [i-CH2); 2.38 (s, 3H, CH3); 2.17 (t, 1H, SH).
FAB-MS: m/z = 365.1 [M+H']; Mr= 364.1 calculated for C,~HZON203S
N,N'-Bis-benryloxycarbonyl L-cystine-bis-2 phenylethylamide (1 Sa) From N,N'-bis-benzyloxycarbonyl-L-cystine and 2-phenylethylamine according to (A).
Yield: 34 %; homogeneous on TLC (solvent system: CHC13/MeOH, 19:1, Rf= 0.8).
N Benryloxycarbonyl-L-cysteine-2 phenylethylamide (1 S) Reduction of 15a according to (B). Yield: 61 %; homogeneous on TLC (solvent system:
cyclohexane/CHCl3/acetic acid, 45:45:10, Rr= 0.6); m.p. 119 - 121 °C;
'H-NMR (d6-DMSO): 8.02 (t, 1H, NH, amide); 7.39-7.18 (m, 11H, arom. H's, NH
ureth.); 5.03 (dd, 2H, CH2 v. Z); 4.06 (m, 1H, H-Ca ); 2.72/2.61 (2xm, 4H, CHz-CH2);
2.22 (bs, 1H, SH).
FAB-MS: m/z = 359.1 [M+H+];1VI<= 358.1 calculated for C'9HzZN2O3S
N,N'-Bis-benryloxycarbonyl-L-cystine-bis-2-(4-hydroxyphenyl)ethylamide (16a) From N,N'-bis-benzyloxycarbonyl-cystine and 2-(4-hydroxyphenyl)ethylamine according to (A). Yield: 71 %; homogeneous on TLC (solvent system:
cyclohexane/CHC13/acetic acid, 45:45:10, Rf= 0.5).
N Benryloxycarbonyl-L-cysteine-2-(4-hydroxyphenyl)ethylamid (16) Reduction of 16a according to (B). Yield: 24 %; homogeneous on TLC (solvent system:
cyciohexane/CHCl3/acetic acid, 45:45:10, R~= 0.6); m.p. 133 - 135 °C;
1H-NMR {d6-DMSO): 9.11 (s, 1H, phenol. OH); 7.98 (t, 1H, NH, amide); 7.38 (m, 6H, arom. v. Z, NH ureth.); 6.99/6.68 (2xd, 4H, arom., phenol. H's); 5.04 (dd, 2H, CH2 v.
Z); 4.05 (m, 1H, H-CQ ); 2.73/2.60 (2xm, 4H, CH2-CH2); 2.26 (bs, 1H, SH).
FAB-MS: m/z = 375.2 [M+H+]; Mr= 374.1 calculated for C'9H22NZO4S
N,N'-Bis-benryloxycarbonyl-L-cystine-bis-.f-chlorobenrylamide (17a) T.____~ _ _._____ _ __ ._.___.
i7 From N,N'-bis-benzyloxycarbonyl-cystine and 4-chlorobenzylamine according to (A).
Yield: 99 %; homogeneous on TLC (solvent system: CHCl3/MeOH, 19:1, Rf= 0.8) N Benryloxycarbonyl-L-cysteine-4-chlorobenrylamide (17) Reduction of 17a according to (B). Yield: 71 %; homogeneous on TLC (solvent system:
cyclohexane/CHC13/acetic acid, 45:45:10, Rr= 0.85); m.p. 137 - 139 °C;
1H-NMR (d6-DMSO): 8.53 (t, 1H, NH, amide); 7.51 (d, 1H, NH ureth.); 7.38-7.26 (m, 9H, arom.. H's); 5.06 (dd, 2H, CH2 v. Z); 4.29 (d, 2H, CH2-Bn); 4.13 (m, 1H, H-Ca );
2.82/2.70 (2xm, 2H, (3-CHZ); 2.53 (bs, 1H, SH).
FAB-MS: m/z = 379.1 [M+H+]; Mf= 378.1 calculated for C,8H19C1N203S
N,N=Bis-benryloxycarborryl L-cystine-bis-3 phenylpropylamide (18a) From N,N'-bis-benzyloxycarbonyi-cystine and 3-phenylpropylamine according to (A).
Yield: 94 %; homogeneous on TLC (solvent system: cyclohexanelCHCl3/acetic acid, 1 S 45:45:10, Rf = 0.7).
N Benryloxycarbonyl L-cysteine-3 phenylpropylamide (18) By reduction of 18a according to (B). Yield: 76 %; homogeneous on TLC (solvent system: cyclohexane/CHCh/acetic acid, 45:45:10, Rf= 0.7); m.p. 104 - 106 °C;
'H-NMR (d6-DMSO): 8.02 (t, 1H, NH, amide); 7.43 (d, 1H, NH ureth.); 7.38-7.15 (m, IOH, arom.. H's); 5.05 (dd, 2H, CH2 v. Z); 4.09 (m, 1H, H-CQ ); 3.12 (m, 2H, N-CHZ);
2.70/2.69 (2xm, 2H, ~3-CH2); 2.58 (t, 2H, CH2-Ph); 2.32 (bs, 1H, SH); 1.70 (m, 2H, CHZ.-CH2-CHZ).
FAB-MS: m/z = 373.2 [M+H+]; Mf= 372.2 calculated for C2oH24N203S
N,N' Bis-benryloxycarbonyl L-cystine-bis-tryptamide (19a) From N,N'-bis-benzyloxycarbonyl-cystine and tryptamine according to (A).
Yield: 75 %;
homogeneous on TLC (solvent system: cyclohexane/CHCl3/acetic acid, 45:45:10, Rf =
0.6).
Benryloxycarbonyl-L-cysteine-tryptamide (19) Reduction of 19a according to (B): Yield: 62 %; homogeneous on TLC (solvent system:
cyclohexane/CHCh/acetic acid, 45:45:10, Rf= 0.7); m.p. I50 - 152 °C;
'H-NMR (d6-DMSO): 10.80 (s, 1H, NH-tryptamine); 8.09 (t, IH, NH amide); 7.54 -6.96 (m, I1H, arom. H's, ureth. NH); 5.05 (dd, 2H, CHZ v. Z); 4.08 (m, 1H, H-C(cc));
3.32 (m, 2H, NHCH~CHz); 2.82 (t, 2H, NHCHZCH2); 2.77/2.65 (2xm, 2H, ~3-CH2);
2.26 (m, 1H, SH).
FAB-MS: m/z = 398.2 [M+H+]; Mf= 397.2 calculated for C21Hz3NsOsS
N,N'-Bis-hexanoyl-L-cystine-bis-benrylamide (20a) Prepared from 6b and hexanoic acid according to procedure (A). Yield: 86 %;
homogeneous on TLC (solvent system: cyclohexane/chloroform/acetic acid, 45:45:10; Rf = 0.6).
'H-NMR (d6-DMSO): 8.48 (t, 1H, NH, amide); 8.02 (d, 1H, NH-ureth.); 7.3-7.2 (m, SH, arom.. H's); 4.41 (m, 1H, H-Ca ); 4.28 (d, 2H, CH2-Bn); 2.80/2.70 (2xm, 2H, (3-i 5 CH2); 2.25 (t, I H, SH); 2.17 (m, 2H, -CHrCO-); 1.49-1.21 (m, 1 OH, alkyl), 0.87 (t, 3H, _CH3).
N Hexanoyl L-cysteine-benrylamide (20) Reduction of 20a according to procedure (B). Yield: 69 %; m.p. 141 - 143 °C;
'H-NMR (d6-DMSO): 'H-NMR (d6-DMSO): 8.48 (t, 1H, NH, amide); 8.02 (d, 1H, NH-ureth.); 7.31-7.2 (m, SH, arom.. H's); 4.40 (m, IH, H-Ca ); 4.22 (d, 2H, CH2-Bn);
2.80/2.70 (2xm, 2H, (3-CH2); 2.3 (bs, 1H, SH); 2.12 (m, 2H, -CHI-CO-); 1.50-1.19 {m, 6H, alkyl), 0.85 (t, 3H, -CH3).
FAB-MS: m/z = 309.2 [M+H+]; Mr= 308.2 calculated for C,6Fi24N2O2S
N,N =Bis-octanoyl-L-cystine-bis-benrylamide (21 a) Prepared from 6b and octanoic acid according to procedure (A). Yield: 86 %;
homogeneous on TLC (solvent system: cyclohexanelchloroform/acetic acid, 45:45:10; Rf = 0.6).
N-0ctanoyl-L-cysteine-benrylamide (21) Reduction of 21a according to procedure (B). Yield: 73 %; m.p. 137 - 139 °C;
__.___ T ___ _ __. _ ._____ _____._T_ ~H-NMR (d6-DMSO): 1H-NMR (d6-DMSO): 8.48 (t, 1H, NH, amide); 8.02 (d, IH, NH-ureth.); 7.3-?.2 (m, SH, atom.. H's); 4.41 (m, 1H, H-CQ ); 4.28 (d, 2H, CH2-Bn);
2.80/2.70 (2xm, 2H, ~i-CH2); 2.25 (t, 1H, SH); 2.17 (m, 2H, -CHz-CO-); 1.49-I.21 (m, IOH, alkyl), 0.87 (t, 3H, -CH3).
S FAB-MS: m/z = 337.2 [M+H+]; Mr= 336.2 calculated for C,gH2gN2OZS
N,N' Bis~decanoyl-L-cystine-bis-benrylamide (ZZa) Prepared from 6b and decanoic acid according to procedure (A). Yield:
quantitative;
homogeneous on TLC (solvent system: cyclohexane/chloroform/acetic acid, 45:45:10; Rf = 0.9).
N Decanoic-L-cysteine-benrylamide (ZZ) Reduction of 22a according to procedure (B). Yield: 33 %; Rf= 0.7); m.p. 138 -140 °C;
'H-NMR (d6-DMSO): 8.46 (t, 1H, NH, amide); 8.02 (d, 1H, NH-ureth.); 7.3-7.2 (m, SH, atom.. H's); 4.4 (m, IH, H-CQ ); 4.29 (d, 2H, CHZ-Bn); 2.80/2.70 (2xm, 2H, [i-CHZ); 2.25 (t, 1H, SH); 2.18 (m, 2H, -CH2-CO-); 1.49-1.19 (m, 14H, alkyl), 0.85 (t, 3H, _CH3).
FAB-MS: m/z = 365.2 [M+H+]; M~= 364.2 calculated for C2d-i32N202S
1. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M.
Drug Disc. Today 1996 2. Wiinsch, E. in Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/I, Springer Verlag, Stuttgart, 1974.
3. Stack, M. S.; Gray, R. D. J. Bio1 Chem. 1989, 264, 4277.
4. Nagase, H.; Fields, C. G.; Fields, G. B. J. Biol. Chem. 1994, 269, 20952.
S. Copeland, R. A.; Lombardo, D.; Giannaras, J.; Decicco, C. P. Bioorg. Med Chem.
Lett. 1995, 5, 1947.
Claims (5)
1. A compound represented by the general formula I, which binds and inhibits matrix metalloproteinases (MMPs), wherein the cysteine moiety contains an unprotected thiol group, the cysteine moiety is in the L- or D-configuration wherein A denotes -CO-, -SO2-, -NH-CO-, or -O-CO-R1 denotes hydrogen, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by halogen, mercapto, hydroxy, alkoxy, amino or vitro, or by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C1-C15 alkyl group substituted by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof.
2. A pharmaceutical composition containing a compound as claimed in claim 1, or the pharmacologically acceptable salts, or optically active forms therof and pharmaceutically acceptable carriers.
3. A therapeutical composition according to claim 2, for the treatment of rheumatoid arthritis and related diseases in which collagenolytic activity is a contributing factor.
4. Use according to claim 3, wherein the dose of the therapeutic agent is 0.1 to 300 mg/kg body weight.
5. Use according to claim 3 or 4, wherein the therapeutic agent is administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97107495 | 1997-05-07 | ||
| EP97107495.0 | 1997-05-07 | ||
| PCT/EP1998/002654 WO1998050351A1 (en) | 1997-05-07 | 1998-05-06 | New cysteine derivatives, processes for their production, and pharmaceuticals containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2289094A1 true CA2289094A1 (en) | 1998-11-12 |
Family
ID=8226770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002289094A Abandoned CA2289094A1 (en) | 1997-05-07 | 1998-05-06 | New cysteine derivatives, processes for their production, and pharmaceuticals containing them |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1034163A1 (en) |
| JP (1) | JP2001525800A (en) |
| KR (1) | KR20010012321A (en) |
| CN (1) | CN1261878A (en) |
| AU (1) | AU7652998A (en) |
| BR (1) | BR9808758A (en) |
| CA (1) | CA2289094A1 (en) |
| TR (1) | TR199903120T2 (en) |
| WO (1) | WO1998050351A1 (en) |
| ZA (1) | ZA983792B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101332157B (en) * | 1998-10-09 | 2012-01-11 | 味之素株式会社 | Cysteine derivatives |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| WO2004090152A1 (en) * | 2003-04-08 | 2004-10-21 | Mitsubishi Gas Chemical Company, Inc. | 2-alkylcysteinamide or salt thereof, process for producing these, and use of these |
| JP5339708B2 (en) * | 2006-10-13 | 2013-11-13 | サンスター株式会社 | Matrix metalloproteinase-8 inhibitor containing cysteine as an active ingredient, and composition for preventing or treating periodontal disease for diabetic patients or persons with impaired glucose tolerance |
| CN107129538B (en) | 2010-04-27 | 2021-07-16 | 西兰制药公司 | Peptide conjugates of GLP-1 receptor agonists and gastrin and uses thereof |
| WO2013064669A1 (en) | 2011-11-03 | 2013-05-10 | Zealand Pharma A/S | Glp-1 receptor agonist peptide gastrin conjugates |
| CN104662038B (en) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | Glucagon analogue |
| TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analogues |
| CN105745222A (en) | 2013-10-17 | 2016-07-06 | 西兰制药公司 | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| TWI670281B (en) | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Gip-glp-1 dual agonist compounds and methods |
| CA2929107C (en) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| ES2883345T3 (en) | 2014-10-29 | 2021-12-07 | Zealand Pharma As | GIP agonist compounds and methods |
| JP6989385B2 (en) | 2015-04-16 | 2022-01-05 | ジーランド ファーマ アクティーゼルスカブ | Acylated glucagon analog |
| USRE49579E1 (en) | 2015-06-08 | 2023-07-18 | University Public Corporation Osaka | Non-peptidic GAPDH aggregation inhibitor |
| BR112019010624A2 (en) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | double acylated glp-1 / glp-2 agonists and composition |
| WO2023201067A2 (en) * | 2022-04-14 | 2023-10-19 | W. L. Gore & Associates, Inc. | Chemical entities |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340147A (en) * | 1965-06-28 | 1967-09-05 | Mead Johnson & Co | Amides of n-acylated cysteines |
| JPH0662529B2 (en) * | 1984-07-13 | 1994-08-17 | 三共株式会社 | Amino acid derivative |
| GB8709547D0 (en) * | 1987-04-22 | 1987-05-28 | Lilly Industries Ltd | Organic compounds |
| AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
| HU216747B (en) * | 1994-05-04 | 1999-08-30 | Novartis Ag. | Fungicide n-sulphonyl and n-sulphinyl amino acid amides as microbiocides producing using and fungicide compositions containing them |
-
1998
- 1998-05-06 AU AU76529/98A patent/AU7652998A/en not_active Abandoned
- 1998-05-06 EP EP98924281A patent/EP1034163A1/en not_active Withdrawn
- 1998-05-06 KR KR1019997010273A patent/KR20010012321A/en not_active Application Discontinuation
- 1998-05-06 CN CN98806716A patent/CN1261878A/en active Pending
- 1998-05-06 JP JP54773498A patent/JP2001525800A/en active Pending
- 1998-05-06 ZA ZA9803792A patent/ZA983792B/en unknown
- 1998-05-06 BR BR9808758-4A patent/BR9808758A/en not_active IP Right Cessation
- 1998-05-06 CA CA002289094A patent/CA2289094A1/en not_active Abandoned
- 1998-05-06 TR TR1999/03120T patent/TR199903120T2/en unknown
- 1998-05-06 WO PCT/EP1998/002654 patent/WO1998050351A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9808758A (en) | 2000-10-03 |
| TR199903120T2 (en) | 2000-05-22 |
| CN1261878A (en) | 2000-08-02 |
| KR20010012321A (en) | 2001-02-15 |
| ZA983792B (en) | 1999-11-08 |
| JP2001525800A (en) | 2001-12-11 |
| AU7652998A (en) | 1998-11-27 |
| WO1998050351A1 (en) | 1998-11-12 |
| EP1034163A1 (en) | 2000-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2289094A1 (en) | New cysteine derivatives, processes for their production, and pharmaceuticals containing them | |
| EP0934267B1 (en) | Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors | |
| AU695507B2 (en) | Metalloproteinase inhibitors | |
| US6218389B1 (en) | Acyclic metalloprotease inhibitors | |
| JP3348725B2 (en) | Hydroxamic acid-based collagenases and cytokine inhibitors | |
| JP4177483B2 (en) | Sulfonylaminocarboxylic acid | |
| AU679474B2 (en) | Carboxy-peptidyl derivatives as antidegenerative active agents | |
| CZ200425A3 (en) | Derivatives of aromatic dicarboxylic acids | |
| SK94196A3 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them, manufacturing process thereof and their use | |
| CA2575928A1 (en) | Compounds for inhibiting copper-containing amine oxidases and uses thereof | |
| KR20000070233A (en) | Bis-Sulfonamides Hydroxamic Acids as MMP Inhibitors | |
| KR20010023001A (en) | Novel Inhibitors of Aggrecanase and Matrix Metalloproteinases for The Treatment of Arthritis | |
| HRP970474A2 (en) | Compounds for and a method of inhibiting matrix metalloproteinases | |
| WO2001010835A1 (en) | Antibacterial agents | |
| ZA200103605B (en) | Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases. | |
| JPH02209861A (en) | Amino acid derivative and enkephalinase inhibitor containing the same as an active ingredient | |
| EP0979816B1 (en) | Hydroxamic acid derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MXPA99010180A (en) | New cysteine derivatives, processes for their production, and pharmaceuticals containing them | |
| HU201005B (en) | Process for producing new n-substituted mercaptopropaneamide derivatives and pharmaceutical compositions comprising such compounds | |
| Hanessian et al. | Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinases | |
| JP2002201168A (en) | Cyclohexane derivative | |
| CA2274889A1 (en) | Bis-sulfonomides hydroxamic acids as mmp inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |